Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ALXN-1920 by Alexion Pharmaceuticals for Kidney Disease (Nephropathy): Likelihood of Approval
ALXN-1920 is under clinical development by Alexion Pharmaceuticals and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData,...